About US
Contact us
-
Will Trump team with Democrats to tweak the latest pricing bills? Maybe, analyst saysAlready the Democrats in Congress are showing they're serious about tackling drug prices, not only with new bills, but a new name-and-shame investigation, too. But those bills are "flawed"—and likely2019/1/15
-
Novartis’ Aimovig fails to win NICE backing amid tight migraine fight with Lilly, TevaWhen a drug is locked in a tight race with two in-class competitors, earlier patient access matters. But Novartis wasn’t so lucky with its first attempt to get blockbuster hopeful Aimovig onto England2019/1/14
-
JPM recap: Must-reads of the week, from FDA to IPO to M&A and moreBig deals, attempts at decent deals and impending IPOs—as usual, the J.P. Morgan Healthcare Conference was awash in deal buzz as well as the occasional rainfall. But that's far from all the talk that2019/1/14
-
Pfizer partners with CytoReason on immune system models for drug discoveryIsraeli-machine learning company CytoReason has announced it has signed a collaboration agreement with Pfizer in which the latter will leverage the former’s technology to create cell-based models of t2019/1/11
-
Daiichi Sankyo receives Japanese marketing approval for two drugsDaiichi Sankyo has obtained marketing approval in Japan for its minnebro and tarlige tablets to treat hypertension and peripheral neuropathic pain (PNP) respectively. Minnebro was identified during a2019/1/11
-
FDA grants breakthrough therapy status to crizanlizumabNovartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the use of crizanlizumab (SEG101) to prevent vaso-occlusive crises (VOCs) in sickle cell diseas2019/1/10
-
UC Berkeley develops drug sponge to soak up chemotherapy side effectsChemical engineers at the University of California, Berkeley (UC Berkeley) have developed a drug sponge that could absorb the residual chemotherapy drug and minimise cancer treatment side effects. To2019/1/10
-
Lilly to acquire Loxo Oncology in deal valued at $8bnEli Lilly has signed a definitive agreement to acquire Loxo Oncology, a biopharmaceutical firm focussed on genomically defined cancers, for a cash consideration of around $8bn, or $235 per share. The2019/1/9
-
Takeda completes $62bn Shire acquisitionJapan-based Takeda Pharmaceutical has officially completed the acquisition of UK headquartered Shire for a total consideration of $62bn. This makes Takeda one of the top ten pharmaceutical companies i2019/1/9
-
Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyoutOn the first day of biopharma’s largest confab, the J.P. Morgan Healthcare Conference, Eli Lilly confirmed that big-ticket M&A is back in fashion in the industry. Lilly said it will acquire targe2019/1/8